Ascendo Biotechnology, Inc.
Hsueh-Yen Ku is the Chief Strategy Officer at Ascendo Biotechnology, Inc. and has previous experience in leadership positions at Phalanx Biotech Group, iCare Diagnostics, and Foxconn. With a background in healthcare venture investments, corporate development, and pharmaceutical & biotech regulatory affairs consulting, Ku is well-educated, holding a Doctor of Philosophy (PhD) in Cell Biology from Yale University and a Bachelor of Science (BS) in Life Sciences from National Taiwan University.
This person is not in any teams
This person is not in any offices
Ascendo Biotechnology, Inc.
We seek to break through the limitations of current immunotherapies and achieve meaningful responses in patients. Our novel approach optimises the natural innate and adaptive immune pathways to reinvigorate the innate immunity of the tumor microenvironment for a comprehensive anti-tumor response. Our mission is to create immunotherapies and vaccines that deliver extraordinary benefits to patients. Our pipeline, underpinned by our revolutionary research in immune response, spans oncology and chronic viral infection, including sepsis and a booster COVID-19 vaccine. We are advancing cutting-edge science to surpass the limits of current checkpoint inhibitors and command an active innate immune response to improve the lives of more patients. Our pipeline is focused on impact creation, and includes NanoCherub™, our nanocomplex platform technology which is accelerating the creation of injectable and oral therapeutic and prophylactic vaccines.